LAWRENCE COREY, M.D.; KENNETH H. FIFE, M.D., Ph.D.; JACQUELINE K. BENEDETTI, Ph.D.; CAROL A. WINTER, R.N.; ANITA FAHNLANDER, R.N.; JAMES D. CONNOR, M.D.; MARIE A. HINTZ, M.D.; KING K. HOLMES, M.D., Ph.D.
Thirty-one patients with first episodes of genital herpes were randomized in a double-blind fashion to intravenous treatment with saline placebo or acyclovir, 5 mg/kg body weight at 8-hour intervals, for 5 days. The median duration of viral shedding from genital lesions after the onset of therapy was significantly shorter for patients given acyclovir (2 days) than for those given placebo (13 days), p < 0.001. Viral shedding from the pharynx, cervix, urethra, and urine were also shorter in acyclovir-treated patients. (p < 0.01 for each comparison). Local and systemic symptoms were shortened by a mean of 5 days and healing of genital lesions by a mean of 12 days in acyclovir-treated patients. (p < 0.01). Complications during treatment, such as extragenital lesions or urinary retention requiring catheterization, developed in four patients given placebo and in none given acyclovir. (p < 0.05). Intravenous acyclovir substantially decreases the symptoms, duration of lesions, and complications of primary genital herpes.
Learn more about subscription options.
Register Now for a free account.
COREY L, FIFE KH, BENEDETTI JK, WINTER CA, FAHNLANDER A, CONNOR JD, et al. Intravenous Acyclovir for the Treatment of Primary Genital Herpes. Ann Intern Med. 1983;98:914–921. doi: 10.7326/0003-4819-98-6-914
Download citation file:
Published: Ann Intern Med. 1983;98(6):914-921.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only